8.4% CAGR for Capsule Endoscopy Market Size Worth $757.51 Million by 2028 – Deep Dive Analysis of 18+ Countries across 5 Key Regions, 50+ Companies Scrutinized | The Insight Partners
09 mars 2023 08h51 HE
|
The Insight Partners
New York, March 09, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Capsule Endoscopy Market Size, Share, Growth and Global Forecast to 2028 - COVID-19 Impact and Global Analysis By...
$11.72 Billion Growth for Enteral Feeding Formulas Market Size to Hit 6% CAGR by 2028 - The Insight Partners
03 nov. 2022 08h34 HE
|
The Insight Partners
New York, Nov. 03, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Enteral Feeding Formulas Market Size, Share and Forecast to 2028 – COVID-19 Impact and Global...
Results from Qu Biologics’ Crohn’s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021
09 juin 2021 09h00 HE
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Human Microbiome Therapeutics Market Size Worth USD 1,098.4 Million by 2027 | Rising Government Initiatives In Microbiome Research Projects And Increasing Drug-Related Side Effects Are Driving The Industry Growth, says Emergen Research
02 mars 2021 08h59 HE
|
Emergen Research
Vancouver, British Columbia, March 02, 2021 (GLOBE NEWSWIRE) -- The global Human Microbiome Therapeutics Market is forecasted to be worth USD 1,098.4 Million by 2027, according to a current analysis...
Trivedi Global, Inc. Announces Research by Gopal Nayak on The Potential Benefits of Biofield Energy Treated Antineoplastic Chemotherapy Drug
04 juin 2019 12h26 HE
|
Trivedi Global, Inc.
Las Vegas, Nevada, US, June 04, 2019 (GLOBE NEWSWIRE) -- Gopal Nayak, today released research results on the beneficial impact of biofield energy treatment on improving physicochemical properties of...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease
03 déc. 2018 07h00 HE
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...